Trial Search Results

Gilead Sustained Virologic Response (SVR) Registry

This Registry is designed to provide long term clinical and virologic follow up in participants who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored hepatitis C virus (HCV) study. This long term follow up study is observational and no treatment is provided for HCV.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Gilead Sciences

Stanford Investigator(s):

Eligibility


Key Inclusion Criteria:

   - Have previously participated in a Gilead-sponsored hepatitis C study and received at
   least one Gilead oral antiviral agent (OAV)

   - Have achieved SVR in a Gilead-sponsored study, as defined in the original treatment
   protocol

   - Provide written, informed consent

   - Be willing and able to comply with the visit schedule and protocol-mandated procedures

Key Exclusion Criteria:

   - Individuals planning to start a new course of hepatitis C therapy including any
   investigational drug or device during the course of the follow-up Registry

   - History of clinically significant illness or any other major medical disorder that may
   interfere with follow up, assessments, or compliance with the protocol

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mindie H. Nguyen, MD
650-498-7878
Recruiting